Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTEGRATED BIOPHARMA INCINBP · Entity 8227 | Director | June 24, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTEGRATED BIOPHARMA INC
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2036-06-24 | Direct | 50,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 50,000 · Balance 50,000 F1: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 25, 2026 15:29 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001382218-26-000001 · primary_doc.xml · derivative · entry 1 Canarick Robert · CIK 0001382218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-24 F1 · derivative.exercise_date: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 17:52 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001345281-25-000006 · primary_doc.xml · derivative · entry 1 Canarick Robert · CIK 0001382218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-18 F1 · derivative.exercise_date: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:09 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | Disposition to issuerStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001345281-25-000001 · primary_doc.xml · derivative · entry 2 Canarick Robert · CIK 0001382218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires 2025-06-02 F2 · derivative.exercise_date: 75% of the options became exercisable on June 2, 2015 with 25% becoming exercisable in twelve (12) equal monthly installments beginning on July 2, 2015. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:09 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantCommon Stock | 175,000 | $0.09 | $15,750.00 |
DisclosureSEC source: 0001345281-25-000001 · primary_doc.xml · nonDerivative · entry 1 Canarick Robert · CIK 0001382218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,233 F1 · kind: 175,000 common stock shares acquired upon exercise of stock option grant dated June 2, 2015. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 15:32 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001345281-24-000001 · primary_doc.xml · derivative · entry 1 Canarick Robert · CIK 0001382218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-08-07 F1 · derivative.exercise_date: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 19:06 UTC | INTEGRATED BIOPHARMA INC INBP · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001382218-23-000001 · primary_doc.xml · derivative · entry 1 Canarick Robert · CIK 0001382218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-07-18 F1 · derivative.exercise_price: The exercise price of each stock option will be the closing price of the Issuer's Common Stock on July 25, 2023, which represents the fifth trading day after the grant date. F2 · derivative.exercise_date: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024. Read SEC document |
| June 20, 2022 Filed Jun 21, 2022 20:19 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001382218-22-000001 · primary_doc.xml · derivative · entry 1 Canarick Robert · CIK 0001382218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-06-20 F1 · derivative.exercise_price: The exercise price of each stock option will be the closing price of the Issuer's Common Stock on June 27, 2022, which represents the fifth trading day after the grant date. F2 · derivative.exercise_date: The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2022, December 31, 2022, March 31, 2023 and June 30, 2023. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:46 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001345281-21-000002 · primary_doc.xml · derivative · entry 1 Canarick Robert · CIK 0001382218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-11-03 F1 · derivative.exercise_price: The Exercise Price of the Stock Option will be the closing prices of the Issuer's Common Stock five trading days after the filing of the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2021, with the Securities and Exchange Commission (the "Issue Date"). F2 · derivative.exercise_date: The option vests and becomes exercisable as follows: 25% (12,500 shares) on the Issue Date, 25% (12,500 shares) on December 31, 2021, 25% (12,500 shares) on March 31, 2022 and 25% (12,500 shares) on June 30, 2022. Read SEC document |
| November 04, 2020 Filed Nov 20, 2020 22:07 UTC | INTEGRATED BIOPHARMA INC inbp · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001345281-20-000006 · primary_doc.xml · derivative · entry 1 Canarick Robert · CIK 0001382218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-11-04 F1 · derivative.exercise_date: The option vests and becomes exercisable as follows: 42% (20,831 shares) on November 19, 2020 and in seven equal monthly installments for the remaining 58% (29,169 shares) beginning on December 1, 2020. Read SEC document |
| May 24, 2019 Filed May 29, 2019 19:38 UTC | INTEGRATED BIOPHARMA INC inbp.ob · Entity 8227 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001382218-19-000001 · primary_doc.xml · derivative · entry 1 Canarick Robert · CIK 0001382218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-05-24 F1 · derivative.exercise_date: The option vests 67% (100,000) on grant date (May 24, 2019) and in twelve equal monthly installments for the remaining 33% (50,000) beginning on July 1, 2019. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 21:44 UTC | INTEGRATED BIOPHARMA INC inpb.ob · Entity 8227 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001382218-16-000003 · primary_doc.xml · derivative · entry 1 Canarick Robert · CIK 0001382218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-11-18 F1 · derivative.exercise_date: The option vests 5/12ths (20,831) on grant date (November 18, 2016) and in 7 monthly installments for the remaining 7/12ths (29,169) beginning on December 1, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.